China's Clover says its Covid-19 vaccines trigger 'strong immune responses' in early trial | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Sunday
October 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
SUNDAY, OCTOBER 01, 2023
China's Clover says its Covid-19 vaccines trigger 'strong immune responses' in early trial

Coronavirus chronicle

Reuters
04 December, 2020, 03:55 pm
Last modified: 04 December, 2020, 03:58 pm

Related News

  • The US needs India to buffer China, and Modi knows it
  • Chinese firm to build solar power plant in Bangladesh
  • US accuses China of global media manipulation
  • China launches first cross-sea bullet train line near Taiwan Strait
  • US soldier Travis King in US custody after expulsion from North Korea to China

China's Clover says its Covid-19 vaccines trigger 'strong immune responses' in early trial

While several vaccine candidates have shown promising trial results in recent weeks, health experts are encouraging the development of more vaccines to tackle a pandemic that has killed more than 1.5 million people globally

Reuters
04 December, 2020, 03:55 pm
Last modified: 04 December, 2020, 03:58 pm
Researchers and clinicians in the field of vaccines are advising not to rush into releasing a vaccine without proper safety analyses. Photo: Reuters
Researchers and clinicians in the field of vaccines are advising not to rush into releasing a vaccine without proper safety analyses. Photo: Reuters

Two coronavirus vaccine candidates developed by China's Clover Biopharmaceuticals triggered strong immune responses in an early-stage human trial and appeared to be safe, the company said on Friday.

The vaccine candidates, one containing an adjuvant from GlaxoSmithKline and the other from Dynavax, induced strong immune responses including neutralizing antibodies and cell-mediated immunity in a Phase 1 clinical trial, Clover said. Adjuvants are ingredients that can boost immune responses.

While several vaccine candidates have shown promising trial results in recent weeks, health experts are encouraging the development of more vaccines to tackle a pandemic that has killed more than 1.5 million people globally.

"Based on the positive Phase 1 results reported and the unprecedented need for Covid-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines," the company said.

The vaccines did not trigger any serious adverse reactions on the 150 adult and elderly people that participated in the trial, the company said.

The candidate with the GSK adjuvant will begin a mid- to late-stage clinical trial this month, and the one with the Dynavax adjuvant is expected to start a separate phase 2/3 trial in the first half of next year.

Preliminary results showed that both candidates could be stored at temperatures of 2C to 8C (35.6F to 46.4F) for at least six months, Clover said. It also said the vaccine could remain stable at room temperatures or temperatures of 40C (104F) for at least one month.

Britain approved Pfizer Inc's Covid-19 vaccine on Wednesday, jumping ahead in a global race to begin the most crucial mass inoculation programme in history.

AstraZeneca Plc, Moderna Inc, and Russian researchers have also announced positive trial results in recent weeks.

Clover's trials are partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), a global epidemic response group.

Top News

Clover Biopharmaceuticals / China / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Containers piled up at Chattogram port. File Photo: TBS
    Exports fetch $4.31 billion in September, lowest since April
  • Remittance earnings in September lowest in 41 months
    Remittance earnings in September lowest in 41 months
  • Photo: UNB
    No discussion held on visa policy with US Assistant Secretary Bitter: Acting Foreign Secretary

MOST VIEWED

  • Photo: TBS
    Habibur Rahman takes charge as 36th DMP commissioner
  • Paperfly aborts flight
    Paperfly aborts flight
  • Photo: Collected
    The top 3 smartwatches of 2023: A glimpse into the future
  • Photo: TBS
    Dhaka traffic slowest in world: Study
  • Harsher bilateral loans set to make external debt repayment tougher
    Harsher bilateral loans set to make external debt repayment tougher
  • Illustration: TBS
    Shokh and Sarika’s quest of return

Related News

  • The US needs India to buffer China, and Modi knows it
  • Chinese firm to build solar power plant in Bangladesh
  • US accuses China of global media manipulation
  • China launches first cross-sea bullet train line near Taiwan Strait
  • US soldier Travis King in US custody after expulsion from North Korea to China

Features

Illustration: Collected

Apology to a life forgotten to live

2h | Features
Photo: Kazi Ashraf Uddin

Coffee: More than a beverage, something of a beloved

5h | Features
The price back to the normal range is possible if the corporations who control the feed market reduce the feed and chick prices. Photo: Noor-A-Alam

Will eggs ever return to their 'normal' price?

7h | Features
Photo & Coffee Sketch: Touseful Isalm

A coffee conversation with Rumi

1d | Features

More Videos from TBS

Apple is bringing new software updates to prevent overheating

Apple is bringing new software updates to prevent overheating

1h | Tech Talk
A unique study cafe in the city

A unique study cafe in the city

34m | TBS Stories
Reserves are falling even as the dollar's share of global payments rises

Reserves are falling even as the dollar's share of global payments rises

4h | TBS Economy
Why is the remittance of banks increasing or decreasing?

Why is the remittance of banks increasing or decreasing?

2h | TBS Economy
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]